Skip to main content

Table 3 Comparison of clinical symptom improvement rate between Ludangshen and placebo group

From: Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial

Variables

FAS analysis

PPS analysis

Ludangshen

Placebo

P value

Ludangshen

Placebo

P value

Fatigue (n)

94

90

 

92

89

 

 Week 1

52 (55.3)

29 (32.2)

0.002

50 (54.3)

29 (32.6)

0.003

 Week 2

81 (86.2)

38 (42.2)

 < 0.001

78 (84.8)

37 (41.6)

 < 0.001

Anorexia (n)

68

70

 

67

68

 

 Week 1

49 (72.1)

25 (35.7)

 < 0.001

48 (71.6)

25 (36.8)

 < 0.001

 Week 2

61 (89.7)

38 (54.3)

 < 0.001

60 (89.6)

36 (52.9)

 < 0.001

Distension (n)

43

34

 

42

33

 

 Week 1

28 (65.1)

14 (41.2)

0.036

27 (64.3)

14 (42.4)

0.059

 Week 2

38 (88.4)

22 (64.7)

0.013

38 (90.5)

21 (63.6)

0.01

Loose stools (n)

48

52

 

48

50

 

 Week 1

32 (66.7)

24 (46.2)

0.039

32 (66.7)

24 (48.0)

0.062

 Week 2

41 (85.4)

32 (61.5)

0.007

41 (85.4)

30 (60.0)

0.005

Shortness of breath (n)

50

50

 

49

49

 

 Week 1

27 (54.0)

21 (42.0)

0.23

26 (53.1)

21 (42.9)

0.312

 Week 2

44 (88.0)

28 (56.0)

 < 0.001

43 (87.8)

28 (57.1)

0.001

  1. FAS full analysis set, PPS per protocol set